Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C

Current Pharmaceutical Design

Volumn 10, Issue 17, 2004, Pages 2101-2109

  Maiellaro, P A ^a   Cozzolongo, R ^a   Marino, Pasquale ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Artificial neural network; Hepatitis C; Interferon; Prediction; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTIFICIAL INTELLIGENCE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 3042684526     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384240     Document Type: Review

References (39)

1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
3. Di Bisceglie AM and Hoofnagle JH. Optimal therapy of Hepatitis C. Hepatology 2002; 36: S121-S127.
4. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
5. Davis GL. Treatment of chronic hepatitis C. BMJ 2001; 323(7322): 1141-2.
6. McHutchison JC, Shad JA, Gordon SC, Morgan TR. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001; 8: 414-20.
7. McHutchison JG, Hoofnagle JH. Therapy of Chronic Hepatitis C. In: Liang TJ, Hoofnagle JH eds. Hepatitis C. Biomedical Research Reports. San Diego (CA): Academic Press 2000; 203-239.
8. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226-231.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
10. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145-51. Review.
11. Layden JE, Layden TJ. How can mathematics help us understand HCV? Gastroenterology 2001; 120: 1546-1549.
12. Forsstrom JJ, Dalton KJ. Artificial neural networks for decision support in clinical medicine. Ann Med 1995; 27(5): 509-517.
13. Lammers RL, Hudson DL, Seamen ME. Prediction of traumatic wound infection with a neural network-derived decision model. Am J Emerg Med 2003; 21(1): 1-7.
14. Andriulli A, Grossi E, Buscema M, Festa V, Intraligi NM, Dominici P, et al. NUD LOOK Study Group. Contribution of artificial neural network to classification and treatment of patients with uninvestigated dyspepsia. Dig Liver Dis 2003; 35(4): 222-31.
15. Haydon GH, Jalan R, Ala-Korpela M, Hiltunen Y, Hanley J, Jarvis LM, et al. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network: analysis of virus and clinical factors. J Viral Hepat 1998; 5(4): 255-64.
16. Khorasani K, Wenig W. An Adaptive Structure Neural Networks with Application to EEG Automatic Seizure Detection. Neural Network 1996; 9(7): 1223-1240.
17. Chetham SM, Barker TM, Stafford W. Neural networks in cardiac electrophysiological signal classification. Australas Phys Eng Sci Med 2002; 25(3): 124-31.
18. Piccolo D, Ferrari A, Peris K, Diadone R, Ruggeri B, Chimenti S. Dermoscopic diagnosis by a trained clinician vs. a clinician with minimal dermoscopy training vs. computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. Br J Dermatol 2002; 147(3): 481-6.
19. Egmont-Petersen M, Schreiner U, Tromp SC, Lehmann TM, Slaaf DW, Arts T. Detection of leukocytes in contact with the vessel wall from in vivo microscope recordings using a neural network. IEEE Trans Biomed Eng 2000; 47(7): 941-51.
20. Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, et al. Modeling of Human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 2003; 14: 46(17): 3631-43.
21. Swiercz M, Mariak Z, Lewko J, Chojnacki K, Kozlowski A, Piekarski P. Neural network technique for detecting emergency states in neurosurgical patients. Med Biol Eng Comput 1998; 36(6): 717-22.
22. Luh JJ, Chang GC, Cheng CK, Lai JS, Kuo TS. Isokinetic elbow joint torques estimation from surface EMG and joint kinematic data: using an artificial neural network model. J Electromyogr Kinesiol 1999; 9(3): 173-83.
23. Chan FH, Yang YS, Lam FK, Zhang YT, Parker PA. Fuzzy EMG classification for prosthesis control, IEFE Trans Rehabil Eng 2000; 8(3): 305-11.
24. Degenhard A, Tanner C, Hayes C, Hawkes DJ, Leach MO, UK MRI Breast Screening Study. Comparison between radiological and artificial neural network diagnosis in clinical screening. Physiol Meas 2002; 23(4): 727-39.
25. Itchhaporia D, Sonw PB, Almassy RJ, Oetegen WJ. Artificial neural networks: current status in cardiovascular medicine. J Am Coll Cardiol 1996; 28(2): 515-21.
26. Doyle HR, Dvorchik I, Mitchell S, Marino IR, Ebert FH, McMichael J, et al. Predicting outcomes after liver transplantation. A connectionist approach. Ann Surg 1994; 219(4): 408-15.
27. Artificial Neural Networks and Diagnosis of Ovarian Dysplasia. From: http://www.mssm.edu/biomath/nnet.shtml. Visited 06/09/2003.
28. National Library of Medicine. From: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed. Visited 01/02/2003
29. Lau DT, Comanor L, Minor JM, Everhart JE, Wuestehube LJ, Hoofnagle JH. Statistical models for predicting a beneficial response to interferon-alpha in patients with chronic hepatitis B. J Viral Hepat 1998; 5(2): 05-114.
30. Rapporti ISTISAN Anno 2001: Indagine Multicentrica sul Profilo d'uso della Ribavirina: un Osservatorio per la Valutazione degli Esiti (IMPROVE). From: http://www.iss.it/publ/rapp/2001/
31. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-961.
32. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
33. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F. et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
34. Bedossa P, Poynard T. METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
35. Ingrassia S, Domma F. Statistical Methods and Perspectives in Neural Network Training from Incomplete Data. From: http://www.ecostat.unical.it/Ingrassia/sis2000.pdf.
36. Craxi A and Licata A. Clinical Trial Results of Peginterferons in Combination with Ribavirin. Sem Liver Dis 2003; 23(S1): 35-46.
37. Douali L, Villemin D, Cherqaoui D. Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. Curr Pharm Design 2003; 9(22): 1817-26.
38. Sardari S, Sardari D. Applications of artificial neural network in AIDS research and therapy. Curr Pharm Design 2002; 8(8): 659-70.
39. Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Design 2002; 8(24): 2139-57.